COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells.
about
Mesenchymal Stem Cells and Myeloid Derived Suppressor Cells: Common Traits in Immune RegulationImmunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS SitesMyeloid suppressor cells and immune modulation in lung cancerRegulation of immune responses by prostaglandin E2Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancerRegulatory myeloid cells in transplantationDendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trialsThe Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer ProgressionImmunosuppression associated with chronic inflammation in the tumor microenvironmentMyeloid-derived suppressor cells in the tumor microenvironment: expect the unexpectedDendritic Cell-Based Immunotherapy Treatment for Glioblastoma MultiformeIntegration of epidemiology, immunobiology, and translational research for brain tumorsMyeloid-derived suppressor cells: the dark knight or the joker in viral infections?Targeting myeloid-derived suppressor cells augments antitumor activity against lung cancer.Directed transport of neutrophil-derived extracellular vesicles enables platelet-mediated innate immune responseInfluence of CYP2C9 and COX-2 Genetic Polymorphisms on Clinical Efficacy of Non-Steroidal Anti-Inflammatory Drugs in Treatment of Ankylosing Spondylitis.Aspirin inhibits the SHH/GLI1 signaling pathway and sensitizes malignant glioma cells to temozolomide therapy.Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma.Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism.Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastasesAssociation between nonsteroidal anti-inflammatory drug use and brain tumour risk: a meta-analysis.Immunosuppressive activity enhances central carbon metabolism and bioenergetics in myeloid-derived suppressor cells in vitro models.Regulation of COX2 expression in mouse mammary tumor cells controls bone metastasis and PGE2-induction of regulatory T cell migration.Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells.Identification of myeloid derived suppressor cells in the peripheral blood of tumor bearing dogs.Epithelial-mesenchymal-transition-like and TGFβ pathways associated with autochthonous inflammatory melanoma development in miceOptimizing dendritic cell-based approaches for cancer immunotherapyInduction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC.Chronic psychological stress induces the accumulation of myeloid-derived suppressor cells in mice.Transcriptional analysis of aggressiveness and heterogeneity across grades of astrocytomas.Transposon mediated integration of plasmid DNA into the subventricular zone of neonatal mice to generate novel models of glioblastoma.IL-12 promotes myeloid-derived suppressor cell recruitment and bacterial persistence during Staphylococcus aureus orthopedic implant infectionPositive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells.Differential migratory properties of monocytes isolated from human subjects naïve and non-naïve to Cannabis.Use of Selective Cyclooxygenase-2 Inhibitors, Other Analgesics, and Risk of GliomaCOX-2 promotes metastasis in nasopharyngeal carcinoma by mediating interactions between cancer cells and myeloid-derived suppressor cells.Single-cell sequencing maps gene expression to mutational phylogenies in PDGF- and EGF-driven gliomasTranscriptional regulation of myeloid-derived suppressor cells.Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer.Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agent
P2860
Q26741252-4B2015A5-3314-4F4C-9961-F1C0742CFF32Q26798402-BDCC1A70-C349-4D52-B9C4-A4B8B0AEB5E2Q26823251-60601A49-1471-44E7-BBD4-5450857A322EQ26849305-E349D247-0919-4895-BEB0-1522F5D95F61Q26863418-04596451-B8CA-4507-BAAD-F4CCFD929660Q26999875-02BE014A-6EA6-4FB7-A2E0-BB05D851B774Q27014829-A7138C62-583A-4E22-B4F9-C7426C70B504Q28076760-46D8F2A8-0321-45FF-8523-695FC38416AFQ28083450-ABFF6A26-9432-496D-B262-DA3853C15590Q28084627-16E0AF46-11E8-448A-94BE-6D0B1B583955Q28087485-465CBBF0-4CC3-496C-88DD-0E8AA6779E5CQ28397886-73980393-50B7-4880-89D8-F8F216647B30Q30411008-8D394196-3779-47E3-9947-196F509BB5E0Q30413623-EC58EA2C-F637-405C-8F58-14CCABB68C1BQ30829121-190D69AB-B73F-4C6C-AA69-8E8AED1B1300Q33584246-940C9089-933B-4574-8E95-8ECB14A5705CQ33657469-9F9AA4DC-5B8D-4883-BE70-320B8EA9926AQ33670136-C668985F-0D68-4F2E-9233-6B7DB0D565ACQ34081723-D15E128A-3722-45FE-8C39-27C3A7FE87DEQ34132305-0EF06206-B1D2-46E4-BA16-BB80CE4F7E57Q34209511-CB031D5C-3A62-4BB2-B00E-6732E4A55FB8Q34326806-6C1D8DE4-13D2-4668-AF2A-16CC12C43CDEQ34431108-8B7BA299-6C2F-4A15-BB3C-875EFE42ED36Q34457611-E699F42D-CE94-4BDC-8DD5-5F39CF804F6AQ34461732-2F1DAA75-6CFB-40BC-BEB2-54524E85C745Q34485253-57DF497C-4BE5-490F-A865-6706E1A4423EQ34637535-5E0A60C2-66E9-4D5F-B655-F61C0F996D38Q34979511-8BDD65BE-D59E-4DA4-AB3F-7DAE5D1F528CQ34994724-E8C94BF4-DF36-4A8A-BC23-D08CF2397CF0Q35022908-CCDD9C2D-C786-49EB-A8C3-81455B700A71Q35162299-529DC4BA-2581-4DEB-A2AF-7BEA35F21AA3Q35328929-81BCE637-7F86-4E53-A183-2C261D7971B6Q35553327-A0DCB0AD-3433-4851-A943-CACE4B480FA9Q35766665-B546D07B-BA10-440A-9BB5-83A6B29A99B8Q35922107-6B898F9F-4B7D-4FEA-9165-78FE53827ADFQ36110362-912B32BA-9FFD-452B-97B6-10AF94EB111AQ36204396-62E0883C-71B4-416A-9783-4B976BC7FA32Q36322351-8E100321-3DFA-4878-A5EC-CEBBC94863E7Q36393212-B6F7CA0F-DC65-41B6-8581-16A551AF36E6Q36483712-64F8C3C6-E782-4D63-ADFF-9D5D305A4CA6
P2860
COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells.
@ast
COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells.
@en
COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells.
@nl
type
label
COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells.
@ast
COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells.
@en
COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells.
@nl
prefLabel
COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells.
@ast
COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells.
@en
COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells.
@nl
P2093
P2860
P1433
P1476
COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells.
@en
P2093
Gary Kohanbash
Hideho Okada
John R Ohlfest
Mitsugu Fujita
Ronald L Hamilton
Stacy A Decker
Wendy Fellows-Mayle
Yoshihiro Komohara
P2860
P304
P356
10.1158/0008-5472.CAN-10-3055
P407
P577
2011-02-15T00:00:00Z